医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Olympus Sets Sights on Growth in Its Refocused Medical Business

2021年12月07日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states. The medtech leader’s approach involves greater focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases that will increasingly impact the global population, as well as more focused investment in next-generation technologies that will enhance patient care pathways.

Three major principles guide the company’s approach:

  1. Focus the portfolio on disease states where Olympus can maximize impact
    Olympus will focus on the disease states where it can maximize its positive impact, including those targeted by its Gastrointestinal, Urology, and Respiratory business areas. Aging populations worldwide face increasing levels of chronic disease that present unmet needs matching Olympus’ competitive strengths, as well as opportunities to continue providing solutions for colorectal cancer, benign prostatic hyperplasia, urological stone disease, urinary disease, and lung cancer. Other medical areas will remain important business components and support Olympus’ goal of striving for greater profitability, contributing to the company-wide goal of at least 5-6% annual growth and an operating profit margin of 20% or higher.
  2. Shape the future by investing in new ways to enhance the standard of care
    Olympus will concentrate on a care pathway oriented approach, procedural optimization, and next-generation solutions development. The company’s innovation pipeline includes plans to optimize its endoscope line through complementary single-use scopes; integrate computer-assisted diagnosis, cloud, and endoscopy workflow management technologies; and explore endoluminal therapy breakthroughs.
  3. Enable Olympus to compete even more effectively on a global scale
    The company’s approach includes enabling factors, such as an expanded global R&D network, stronger Medical and Scientific Affairs, and a more centralized Quality Assurance and Regulatory Affairs function. Merger and acquisition momentum is expected to stay strong via the Olympus business development function, which drove significant acquisitions over the past 2 years. Additionally, the new Olympus wholly owned corporate venture capital fund will prioritize early-stage investments and aim to stimulate next-generation innovations.

Olympus’ new direction comes on the back of strong half-year figures, including a record operating profit margin of 18.5% and strong year-on-year growth of 31%, as announced on November 5. Medical business revenue is expected to reach a record high for fiscal year 2022. Olympus also reiterated its goal of operating with a 20%-plus profit margin and a midterm annual growth rate of 5-6% in fiscal year 2023.

Since 2019, Olympus has completed the sale of its Imaging business and announced the impending transition of its Scientific Solutions business into a newly established, wholly owned subsidiary. A package of operational changes brought about enhancements in efficiency, profitability, R&D processes, and customer care.

“We are witnessing stunning changes to the global healthcare industry due to the aging of populations, the rise of chronic diseases, integration of digital technologies, health and biotech advancements and a growing emphasis on less-invasive treatments,” said Yasuo Takeuchi, President and CEO of Olympus. “With the successful transformation of Olympus since 2019, we have become a global medtech leader. Today we have unveiled a unifying value creation direction that is designed to elevate the standard of care, optimize the treatment journey for patients and healthcare professionals, and benefit all stakeholders, while accelerating our ability to deliver on the profitability and growth targets we have set.”

About Olympus

Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211206005877/en/

CONTACT

For further information:

Yuka Horimoto: +81-90-2490-1071 / Yuka.Horimoto@olympus.com

Robert John Tasker: +852 61856198 / Robert.Tasker@fleishman.com

Joy Kam: +852 64233931 / Joy.Kam@fleishman.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Impella RP Flex with SmartAssistによる治療を世界で初めて実施
  • MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
  • ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia
  • クラウン・バイオサイエンスの新論文では、マッチング PDXによるIn Vitro 3Dオルガノイドの臨床的に意義のある抗がん剤開発への適用を詳述
  • Sermo调查发现,全科医生接受PrEP药物教育可提高此类药物在患者中的采用率